Q3 2024 EPS Estimates for Qiagen (NYSE:QGEN) Lifted by William Blair

Qiagen (NYSE:QGEN) – Research analysts at William Blair upped their Q3 2024 earnings per share estimates for shares of Qiagen in a research note issued to investors on Wednesday, August 7th. William Blair analyst A. Brackmann now forecasts that the company will post earnings of $0.54 per share for the quarter, up from their prior estimate of $0.52. The consensus estimate for Qiagen’s current full-year earnings is $2.15 per share. William Blair also issued estimates for Qiagen’s Q4 2024 earnings at $0.60 EPS and Q4 2025 earnings at $0.61 EPS.

QGEN has been the subject of a number of other research reports. Robert W. Baird boosted their target price on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. upped their price target on Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday, June 18th. Stifel Nicolaus lowered their price target on Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research report on Wednesday, May 1st. Finally, Wolfe Research raised Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price target for the company in a research report on Thursday, June 27th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.10.

Qiagen Trading Down 0.2 %

NYSE QGEN opened at $45.42 on Friday. Qiagen has a 1-year low of $34.74 and a 1-year high of $46.55. The company has a current ratio of 1.77, a quick ratio of 1.45 and a debt-to-equity ratio of 0.27. The stock has a 50-day moving average of $42.85 and a 200-day moving average of $43.04. The firm has a market cap of $10.36 billion, a PE ratio of 30.46, a price-to-earnings-growth ratio of 3.19 and a beta of 0.40.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.03. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The company had revenue of $496.00 million during the quarter, compared to analyst estimates of $495.45 million. During the same quarter in the previous year, the company posted $0.53 EPS. Qiagen’s revenue for the quarter was down .2% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Qiagen by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 8,815,467 shares of the company’s stock worth $382,856,000 after acquiring an additional 83,371 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in shares of Qiagen by 0.8% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,481,873 shares of the company’s stock worth $151,526,000 after buying an additional 26,078 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Qiagen by 8.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 24,066,569 shares of the company’s stock worth $1,045,211,000 after buying an additional 1,809,486 shares during the last quarter. Optiver Holding B.V. grew its stake in shares of Qiagen by 1,211.4% in the 4th quarter. Optiver Holding B.V. now owns 47,212 shares of the company’s stock worth $2,050,000 after buying an additional 43,612 shares during the last quarter. Finally, Sei Investments Co. grew its stake in shares of Qiagen by 49.0% in the 4th quarter. Sei Investments Co. now owns 1,196,476 shares of the company’s stock worth $51,963,000 after buying an additional 393,553 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.